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http://www.biomedcentral.com/1471-2466/12/47CASE REPORT Open AccessProgressive dyspnoea following the treatment of
Mycobacterium abscessus infection in an
individual with relapsing granulamatosis with
polyangitis (Wegener’s), complicated by hearing
loss requiring cochlear implantation
Senyo K Tagboto1* and Ajay G Venkatesh2Abstract
Backgound: Granulomatosis with polyangitis (Wegener’s) is a vasculitic disease predominantly affecting the lungs,
skin, kidneys, ears, nose and throat. Mycobacterium abscessus is an uncommon rapidly growing mycobacterium
causing sporadic lung disease. This is the first report of both GPA and Mycobacterium abscessus pulmonary disease
reported in literature.
Case Presentation: We present a case report of a 33 year old Caucasian man with relapsing disease complicated
by pulmonary infection with Mycobacterium abscessus. He subsequently required bilateral cochlear implantation for
progressive sensori-neural hearing loss. His M. abscessus was treated successfully with a prolonged course of
antimicrobial therapy. His Granulomatosis with polyangitis (Wegener’s) relapsed towards the end of antimicrobial
therapy and required treatment. Shortly after completing his antimicrobial therapy and relapse, he developed
progressive dyspnea due to pulmonary fibrosis.
Conclusion: The potential causes of his progressive dyspnoea are discussed including the potential role of his
underlying disease and treatment.
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Pulmonary fibrosisBackground
Granulomatosis with polyangitis (GPA) is a vasculitic
disorder affecting small and medium sized arteries. It
commonly presents with ear, nose and throat, pulmon-
ary, skin and renal manifestations. Anti-neutrophil cyto-
plasmic antibodies (ANCA) are present in 82 – 94% of
people with GPA, primarily directed against proteinase 3
(PR3) [1]. The diagnosis may also be made by tissue
biopsy.
Mycobacterium abscessus is one of a group of rap-
idly growing mycobacterium (RGM), (including M.* Correspondence: senyo2@hotmail.com
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distribution, and reproduction in any mediumfortuitum, M. chelonae, M. smegmatis, M. mucogenicum,
M. neoaurum, and M. peregrinum). They are ubiquitous
in nature and can be found in soil, bioaerosols, and
water. Several strains have intrinsic resistance to many
antibiotics, which complicates treatment. M. abscessus is
the most pathogenic of this group and occasionally
causes pulmonary infection, usually but not invariably in
immunocompromised patients or people with under-
lying lung disease such as cystic fibrosis [2,3]. We could
find no reports of this infection complicating GPA.
We report a case of pulmonary M. abscessus infection
in a 33 year old man with GPA, successfully treated with
amikacin, clarythromycin and cefoxitin. His sensori-
neural hearing loss progressed substantially during treat-
ment and he eventually required bilateral cochleared Central Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Tagboto and Venkatesh BMC Pulmonary Medicine 2012, 12:47 Page 2 of 5
http://www.biomedcentral.com/1471-2466/12/47implants. His GPA relapsed towards the end of his treat-
ment and required induction therapy with cyclophospha-
mide and eventually rituximab to achieve remission.
Shortly after remission, he developed dyspnoea which
was diagnosed to be a consequence of pulmonary fibro-
sis. M. abscessus is classified as an atypical and rapidly
growing mycobacteria (RGM). It is the most common
causative RGM isolated in pulmonary infections from
this group of pathogens.
Case Presentation
A 33 year old man was seen in the emergency department
of our Hospital in June of 2010 with a 2 week history of fa-
tigue and what he described as a gurgling discomfort in
his chest. He was additionally coughing up blood stained
sputum. He had a past medical history of GPA, diagnosed
elsewhere in 2003 when he presented with progressive
deafness, loss of taste, recurrent sinusitis, arthralgia and
haemoptysis. He had relapsed 3 times since his initial pres-
entation. He was on prednisone 10milligrams daily and
mycophenelate motefil (MMF) 1 gram twice daily. He was
also on atenolol for hypertension. He was a life-long non-
smoker, but lived with both parents who were smokers.
C-reactive protein (CRP) levels were reported at
< 7 grams/millilitre and erythrocyte sedimentation rate
(ESR) at 32millimetres/hour. A chest x-ray showed pul-
monary nodules with cavitation in both lungs. Three sep-
arate sputum cultures demonstrated M. abscessus
infection confirmed by gene sequencing. Proteinase 3
antibody titres over the next few months remained in the
negative/equivocal range 4–6 U/ml (0–5 negative, 6–9Collapsed nasal br
implants in a patie
granulo
Figure 1 Collapsed nasal bridge and cochlear implants in a patient wequivocal, >9 positive). Antinuclear antibodies, double
stranded DNA antibodies and extractable nuclear anti-
bodies were all negative.
Following susceptibility testing of his mycobacterial in-
fection and on the advice of an infectious disease special-
ist, he was treated with amikacin 7.5 mg/kg q12h
intravenously (iv), cefoxitin 2 g q4h iv and clarythromycin
500 mg bid orally (po) for 2 months, followed by clarithro-
mycin and amikacin to complete 12 months of antimicro-
bial therapy. This mycobacterium isolate was not was
susceptible to oral antibiotics except clarithromycin.
He was counselled about the side effects of amickacin
including deafness and consented to treatment. Aspergil-
lus fumigatus was isolated from his sputum on two occa-
sions and was treated with voriconizole. His MMF dose
was slowly reduced to decrease the potential risk of im-
munosuppression interfering with the successful treat-
ment of his infection.
His respiratory symptoms improved until Febuary
2011 (8 months after presenting to our Unit) when he
again began to feel unwell with lethargy, loss of taste,
nasal crusting and discharge, senineural hearing loss,
blurred vision and other symptoms. His Birmingham
Vasculitis Score (BVAS) was 24 at the time [4]. Further-
more the bridge of his nose was noted to have begun
to collapse (Figure 1). Repeat ANCA tests were in the
range 5–6 U/ml. However his CRP now measured
108 g/ml and his ESR 75 mm/Hr. A bronchoscopy
demonstrated endobronchial involvement and a trans-
bronchial biopsy and was reported to be consistent with
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not treated with MESNA and after 2 months of treat-
ment, developed hemorrhagic cystitis. His treatment was
then changed to rituximab 375 mg/m2 weekly for 4 weeks.
This treatment was delayed as we sought funding for his
treatment which eventually started in the middle of June
2011. Shortly thereafter, his symptoms resolved and he
went into clinical remission. His PR3 levels were of 0–1
U/ml and he was kept on maintenance therapy with
azathioprine.
He completed his course of rituximab and antibacterial
treatment in July 2011. Sputum cultures were now per-
sistently negative and his cavitating pulmonary nodules
had markedly improved, confirmed on Chest x-ray
(Figure 2) and CT scan. However, shortly afterwards, he
began to complain of dyspnoea. Serial spirometery
showed a progressive decline in pulmonary function
(Figure 3). His reduction in FEV1 was not reversible with
nebulised salbutamol. Bronchoscopy was carried out in
November 2011 and reported as showing evidence of
widespread airways scarring particularly in the left main
stem bronchus (approximately 65%) with sparing of the
main trachea and carina.
During this period he developed severe mixed hearing
loss in his right ear and profound sensory-neural deaf-
ness in his left ear with no measurable hearing above a
frequency of 500 Hz and noise perception at 60 dB of
0%. This qualified him for cochlear implants, which were
inserted in August 2011, and improved his hearing
dramatically.Discussion
Patients with GPA are typically treated with initial immuno-
suppressive therapy (commonly cyclophosphamide and glu-
cocorticoids) followed by maintenance therapy with
azathioprine or methotrexate, typically for 12–18 months.
However, relapses are common, occurring on average








Figure 2 Progressive change in lung function shortly after completing treInfections have been hypothesized to trigger some dis-
ease flares by inducing expression of the ANCA antigens
(PR3 and MPO) on the surface of circulating neutrophils.
This can, in the presence of ANCA, lead to neutrophil de-
granulation, the release of oxygen radicals, and vascular
injury [5].
A recent study comparing cyclophosphamide with
rituximab for induction therapy concluded that the rate
of remission induction at six months was significantly
higher with rituximab (67 versus 42%). There is however
no conclusive evidence that rituximab is superior to
cyclophosphamide although subgroup analysis raises the
possibility that rituximab may be optimal therapy for
patients with relapsing disease [6].
Pulmonary fibrosis has been rarely reported in patients
with vasculitis and typically with active disease rather
than after remission [7]. Additionally, substantial tissue
fibrosis has been reported from kidney biopsies of
patients with other ANCA associated disease [8]. ANCA
antigens have a number of bioeffects and are potent acti-
vators of latent TGF-β [9] which is known to promote
fibrogenesis [10]. The binding of circulating ANCA
results in neutrophil degranulation and the release of re-
active oxygen species which have been suggested may
lead to subsequent injury and consequent fibrosis [11].
Although pulmonary fibrosis is a well-recognised com-
plication of M. tuberculosis infections, we could find no
case reports of this complicating M. abscessus lung disease.
The isolation of M. abscessus may represent infection or
colonization. However this gentleman had a short history
or progressive respiratory symptoms and repeated isola-
tion of mycobacteria from cultures which raises the likeli-
hood of indolent disease [12]. Histological evidence to
prove invasive disease may be helpful but was not done.
Additionally, he was seen by our infectious diseases spe-
cialist team who felt that he likely had true infection
warranting treatment.
Pulmonary fibrosis has been occasionally reported to





atment for GPA and Mycobacterium abscessus pulmonary infection.
Pre-treatment X-rays showing
cavitating granulomas
Post-treatment X-rays showing 
substantial resolution
Figure 3 Chest radiographs demonstrating cavitation granulomas in a patient with GPA before and after treatment.
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view to identify non-infectious pulmonary complications
associated with the newer biologic agents (rituximab, cer-
tolizumab, golimumab, tocilizumab and abatacept) used
for the treatment of rheumatic conditions. Interstitial lung
disease, idiopathic pulmonary fibrosis, allergic pneumon-
itis, and culture-negative pneumonia have been reported.
Our patient developed progressive dyspnea shortly
after completing induction therapy with cyclophospha-
mide followed by rituximab, towards the end of the
treatment of his M. abscessus infection. Although a chest
x-ray and computed tomography scans showed an im-
provement in the radiological appearances of his lungs,
there was a marked deterioration in his FEVI, PEF and
FVC suggesting both obstructive and restrictive lung dis-
ease. Bronchoscopic evaluation showed pulmonary fibro-
sis with arrears of significant narrowing.
Ototoxicity was an unfortunate consequence of both
his GPA and prolonged treatment with amikacin. Fortu-
nately, cochlear implants may be used in this instance
and have been gaining popularity since they were first
used 50 years ago for treating sensorineural hearing loss.
They are surgically implanted prostheses that use elec-
trical stimulation to provide hearing. Concerns about the
ototoxicity of amikacin have led to small but successful
trials of aerosolized amikacin in M. avium intracellulare
pulmonary infections [15]. Unfortunately, the efficacy of
this mode of administration in M. abscessus infections
remains unknown.
The presence of Aspergillus spp. in sputum has been
shown to be associated with the isolation of non-
tuberculous mycobacteria in a study in involving patients
with cystic fibrosis (66.7% vs. 21.5% of controls) in sputum
samples [3]. Interestingly our patient had Aspergillus sp
isolated from his sputum on two occasions during the
treatment of his M. abscessus infection. It has been sug-
gested that the strong association between infection with
NTM and Aspergillus spp. may reflect the severity of thepulmonary disease or that these organisms may create fa-
vorable conditions for the co-colonization such as by alter-
ing mucociliary clearance [3].
Conclusions
Our patient developed progressive dyspnea shortly after
completing induction therapy with cyclophosphamide
followed by rituximab. This coincided with the end of
the treatment of his M. abscessus infection.
Despite a substantial improvement in the radiological
appearances of his lungs, there was a marked deterioration
in his pulmonary function tests and bronchoscopic evalu-
ation demonstrated pulmonary scarring with arrears of
significant narrowing.
It is difficult to be certain of the exact cause of his pro-
gressive pulmonary fibrosis. However it is plausible that
his GPA, cyclophosphamide and rituximab all contributed
to this because of their known potential lung toxicity. The
role of M. abscessus if any is much less clear.
Consent
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